1 of 1

Unraveling Immune Diversity in Latin America:

Insights from the JAGUAR Project and Lupus Research in Mexico

Evelia Lorena Coss-Navarrete 1, Ana Laura Hernández-Ledesma 1, Diego Ramírez-Espinosa 1, Alejandra Schäfer 1, Grecia Sevilla-Parra 1, Tarran Rupall 3, Matiss Ozols 3, Anna Lorenc 3, Carla Jones 3, Tinajero-Nieto Lizbet 4, Torres-Valdez Estefania 5, Peña-Ayala Angélica 4,6, Felix-Rodríguez Guillermo 7, Rosetti-Sciutto Florencia 8, Fernández-Valverde Selene Lizbeth 9, Gutierrez-Arcelus María 10,11,12, Alpízar-Rodríguez Deshiré 13, Gosia Trynka* 2, Alejandra Medina-Rivera* 1.

1: Laboratorio Internacional de Investigación sobre el Genoma Humano (LIIGH-UNAM), Mexico; 2: Escuela Nacional de Estudios Superiores Unidad Juriquilla, Universidad Nacional Autónoma de México, Juriquilla, Querétaro, México; 3: Wellcome Sanger Institute, UK; 4: Hospital General Regional No. 1, Instituto Mexicano del Seguro Social, Querétaro, Santiago de Querétaro, México; 5: Hospital General Regional No. 2, Instituto Mexicano del Seguro Social, El Marqués, México; 6: Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Ciudad de México, Mexico; 7: Hospital Star Médica, Querétaro, México; 8: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México; 9: University of New South Wales (UNSW), Sidney, Australia; 10: Division of Immunology, Boston Children’s Hospital, Boston, MA, USA; 11: Harvard Medical School, Boston, MA, USA; 12 Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA; 13 Centro Medico Althea, Cuernavaca, Morelos, Mexico.

Evelia Coss

ecoss@liigh.unam.mx

@EveliaCoss

Presenter

MOTIVATION:

AIM: To address how genetic diversity in healthy individuals shapes immunity, resulting in differences in responses to infections and susceptibility to diseases.

STRENGTH: Genetic richness of Latin American populations and environmental diversity.

HOW: The use of single-cell technologies (scRNA-Seq, scATAC-Seq and scCITE-Seq) to identify how diverse ancestries impact gene expression and the composition of immune cells.

STUDY DESIGN:

Figure 2. Methodological approach. Volunteers from Mexico will provide blood samples for PBMC isolation and analysis. Using single-cell technologies (scATAC-seq, scRNA-seq, CITE-seq) and whole genome sequencing (WGS), the study will investigate ancestry’s influence on gene expression and immune cell composition. Health, lifestyle, and environmental data will also be collected.Whole Genome Sequencing (WGS), PBMC: Peripheral blood mononuclear cells.

Volunteers recruitment

  • Healthy volunteers and SLE patients from Mexico
  • Born in the country; parents (preferably grandparents) also born there.
  • No chronic diseases (volunteers); no additional chronic diseases (SLE).
  • No Pregnancy; No biological, hormonal, or antibiotic treatments (SLE).
  • Glucocorticoids <10 mg/day (SLE).
  • Signed informed consent INB, UNAM ethics Committee 093.H.

RESULTS:

CONCLUSION AND PERSPECTIVES:

Metadata collection with biobank standards

9 : 1

Socioeconomic

Genetics

Environmental

20-40 years old

Highest Lupus Prevalence Among Hispanic Females: 120.7 per 100,000

Ancestry Influences on Lupus Manifestations and Severity

SLE

Chronic

Autoimmune

Multifactorial

Multisystemic

Heterogeneous

 Characteristic

SLE

(n=104)

Healthy controls

(n=121)

Age (SD)

39.08 (11.53)

31.1 (8.54)

Age range (years old)

18 - 67

18 - 49

Years with diagnosis (SD)

9.15 (8.0)

NA

SLE family history (n,%)

27 (25.96%)

NA

Nephritis (n,%)

18 (17.31%)

NA

Disease activity (SLEDAI)

Without activity (0 pts) (Zero)

Mild activity (1-4 pts)

Activity (≧4 pts)

15 (14.42 %)

16 (15.38%)

73 (70.19%)

NA

SLEDAI mean score (SD)

16.30 (16.0)

NA

Consumption of corticoids (n,%)

14 (13.46%)

NA

Daily dose of corticoids (Median, %)

5 mg (8.65 %)

NA

Consumption of other treatments (n,%)

61 (58.65 %)

NA

Systemic Lupus Erythematosus

Demographic Overview of Study Participants

This project was supported by the Chan-Zuckerberg Initiative (CZI). We thank LAVIS members Luis Aguilar, Alejandro León, and Jair García, and LIIGH members Carina Uribe Díaz, Alejandra Castillo Carbajal, and Christian Molina Aguilar for their support. Ana Laura Hernández-Ledesma, a doctoral student from UNAM, received fellowship CVU/Becario (711015/790972) from CONAHCYT. Evelia Coss is postdoctoral from CONAHCYT (CVU 781634). I sincerely appreciate Mauricio Guzmán, Paty Rodil Garcia, and Andy Bermeo de Jesus for their invaluable help on social media. My heartfelt gratitude goes to Mariana Villegas, Nadia Estrada, Sofia Hernandez, and Francisco Ramirez for their dedication in sampling and blood collection. We also thank the Blood Bank of Querétaro, especially Dr. Said González and Dr. Mercedes.

ACKNOWLEDGEMENTS:

Figure 1. Geographic distribution of individuals with Systemic Lupus Erythematosus in Mexico (n=1172). Graph by: Ana Hernández-Ledesma from LupusRGMX [1, 2].

COMMUNITY ENGAGEMENT:

  • Cell type isolation and storage
  • Sample shipment to Sanger
  • Bucketing of cells

Single Cell Omics

PBMC collection & genetic profiling

PBMC isolation

scRNA-seq scATAC-seq scCITE-seq

WGS

PBMC isolation from volunteers

Number of SLE patients

[1] Jiwrajka N & Anguera MC. 2022. J Exp Med. PMID: 35510951

[2] Izmirly PM, et al. 2021. Arthritis Rheumatol. PMID: 33474834

Both Conditions

Only SLE

Metadata

General information

Lifestyle

Medical history

Environmental variables

Comorbidities

Medication use

Time since diagnosis

Age at diagnosis

Reproductive health

Sleep quality

Physical activity

Figure 3. Geographic distribution of study participants.. A) Geographic distribution of participants. B) Sex distribution of healthy controls and SLE patients. C) Age group distribution in both groups. yo: years old.

REFERENCES:

Figure 4. Clinical and diagnostic characteristics of SLE patients. A) Distribution of patients across healthcare centers. B) Diagnosis time. C) Distribution of medications used. D) Presence of comorbidities.

Clinical and Diagnostic Characteristics of SLE Patients

Grandparents' Ancestry

Figure 5. Ancestry distribution of participants based on their grandparents' origin.

We aim to recruit 200 healthy volunteers and 200 SLE patients. Join us!

  • We are generating high-quality data on SLE patients and healthy controls in Mexico to improve the representation of Latin American diversity.
  • Our project enhances functional genomic studies in Latin American populations, addressing gaps in global research.
  • Community engagement strengthens our impact, fostering a more significant social contribution through science communication.

Internal use